Home » Topics » Hematologic, BioWorld Science

Hematologic, BioWorld Science
RSS

Protagonist Therapeutics reports initial phase II data on PTG-300 in polycythemia vera

May 8, 2020

Positive topline results from global phase III INNO2VATE program of vadadustat

May 6, 2020

Regenacy Pharmaceuticals discloses HDAC1 and/or HDAC2 inhibitors

April 21, 2020

Chinese regulatory approval granted to initiate phase II/III study of HBM-9161 in ITP

April 16, 2020

SP-8008 prevents thrombus formation without inducing bleeding by blocking vWF-GP Ib interaction

April 15, 2020

New t-PA, u-PA and plasmin inhibitors presented by Alxerion Biotech

April 9, 2020

Catalyst announces pivotal phase III design for MarzAA

April 8, 2020

FDA approves Reblozyl to treat anemia in MDS

April 6, 2020

FDA approves Sevenfact for hemophilia A and B

April 2, 2020

FORMA Therapeutics identifies new pyruvate kinase PKLR activators

April 2, 2020

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for April 10, 2026.
News in brief
BioWorld Asia
BioWorld Asia briefs for April 7, 2026
MMP inhibitors divulged in Accure Therapeutics patent
BioWorld Science
Accure Therapeutics has reported new oligopeptide derivatives acting as matrix metalloproteinase-2 (MMP-2) and MMP-9 inhibitors. As such, they are described as...
MSD discloses new HCN1/2 blockers
BioWorld Science
Merck Sharp & Dohme LLC (MSD) has synthesized new indazole derivatives acting as potassium/sodium hyperpolarization-activated cyclic nucleotide-gated channel 1...
Orexin OX2 receptor agonists disclosed in Vertex Pharmaceuticals patent
BioWorld Science
Vertex Pharmaceuticals Inc. has patented new macrocyclic sulfonamide orexin OX2 receptor agonists potentially useful for the treatment of amyotrophic lateral...